LifeMD price target raised to $14 from $12 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on LifeMD (LFMD) to $14 from $12 and keeps a Buy rating on the shares. The company reported a Q4 beat and expects solid growth in 2025, the analyst tells investors in a research note. The firm says LifeMD has a comprehensive care platform that includes its pharmacy benefits infrastructure, which helps patients access branded GLP-1 medications.